Neuropeptide Y conjugated to saporin alters anxiety-like behavior when injected into the central nucleus of the amygdala or basomedial hypothalamus in BALB/cJ mice.
Neuropeptide Y (NPY) is a 36-amino-acid neuromodulator that is distributed throughout the central nervous system and has been implicated in a wide range of neurobiological responses including the integration of emotional behavior. The anxiolytic properties of NPY are modulated by NPY signaling in the hippocampus and in the central (CeA) and basolateral (BLA) nuclei of the amygdala. Recently, the neurotoxin saporin, when conjugated to NPY (NPY-SAP), was shown to selectively kill NPY receptor-expressing neurons and has been used as a tool to study the central NPY neurocircuitry involved with feeding behaviors. Here we determined if NPY-SAP can be used as a tool to study the central NPY neurocircuitry that modulates anxiety-like behaviors. BALB/cJ mice were given injection of either NPY-SAP or a control blank saporin (B-SAP) into the CeA or the basomedial hypothalamus (BMH) as a control injection site. The elevated zero maze test was used to assess anxiety-like behavior and NPY-SAP-induced lesions were verified using NPY Y1 receptor (Y1R) immunoreactivity (IR). Results showed that injection of NPY-SAP into the CeA site-specifically blunted Y1R IR in the CeA which was associated with a significant increase in anxiety-like behavior. Injection of NPY-SAP into the BMH, while locally blunting Y1R IR, promoted a compensatory increase of Y1R IR in the BLA and the CA3 region of the hippocampus which was associated with a significant reduction of anxiety-like behavior. The present set of experiments suggest that the NPY-SAP neurotoxin may be a useful tool for studying the NPY neurocircuitry that modulates anxiety-like behaviors.
Lyons
Angela M
AM
Department of Psychology, University of North Carolina at Chapel Hill, CB#3270, Chapel Hill, NC 27599-3270, USA.
Thiele
Todd E
TE
D000679:Amygdala / Q000187:drug effects*; D000818:Animals; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D007031:Hypothalamus / Q000187:drug effects*; D007150:Immunohistochemistry; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D009478:Neuropeptide Y / Q000737:chemistry / Q000627:therapeutic use*; D054789:Ribosome Inactivating Proteins, Type 1 / Q000737:chemistry / Q000627:therapeutic use*; D000076985:Saporins
D014151:Anti-Anxiety Agents; D009478:Neuropeptide Y; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins